NovoCure (NVCR) Net Income towards Common Stockholders Growth (5y) (2019 - 2026)
NovoCure (NVCR) Net Income towards Common Stockholders Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.35% |
| Mar 31, 2026 | -76.71% |
| Dec 31, 2025 | -47.50% |
| Sep 30, 2025 | -43.17% |
| Jun 30, 2025 | -92.24% |
| Mar 31, 2025 | -60.60% |
| Dec 31, 2024 | -77.21% |
| Sep 30, 2024 | -77.94% |
| Jun 30, 2024 | -92.28% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -24.67% |
| Sep 30, 2023 | -33.44% |
| Jun 30, 2023 | -29.92% |
| Mar 31, 2023 | -20.69% |
| Dec 31, 2022 | -27.79% |
| Sep 30, 2022 | -18.24% |
| Jun 30, 2022 | -2.54% |
| Mar 31, 2022 | 23.76% |
| Dec 31, 2021 | -3.60% |
| Sep 30, 2021 | 17.15% |